The Trump administration is shifting away from funding next-generation Covid-19 vaccines and are instead investing $500M in a vaccine project involving producing vaccines from chemically inactivated whole viruses, Nidhi Subbaraman and Liz Essley Whyte of The Wall Street Journal reports. The technique is a throwback to how flu vaccines were made decades ago. The goal of the project is to make “universal” vaccines that protect against multiple strains of the virus at once. Companies who make Covid-19 vaccines include Pfizer (PFE), BioNTech (BNTX), and Moderna (MRNA).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Hold Rating on Pfizer Amid Political Challenges in Biopharmaceutical Sector
- Pfizer price target raised to $25 from $24 at UBS
- Notable open interest changes for April 30th
- Pfizer Positioned for Growth: Buy Rating Affirmed Due to Operational Efficiency, Strategic Capital Allocation, and Undervaluation
- Pfizer’s Mixed Q1 Results and Uncertain Long-Term Prospects Justify Hold Rating